Algo version: 0.98b
Bafna Pharmaceuticals is listed at the NSE Exchange
Bafna Pharmaceuticals [BAFNAPH.NS]
NSE Sector: Healthcare Industry:Drug Manufacturers—Specialty & Generic

Is Bafna Pharmaceuticals stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Bafna Pharmaceuticals pays dividends. Last time was Thursday 1st of January 1970 where the investors holding the stock on Thursday 19th of September 2013 were paid INR0.06 per share. Over the last 1 times between 2013 and 2013, Bafna Pharmaceuticals has paid INR0.06 with an average of INR0.06 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Bafna Pharmaceuticals 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was INR3.55, you would have made a profit of INR77.24 per share or 2 175.77%

No, the average daily trading liquidity for Bafna Pharmaceuticals is INR3 159 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

Bafna Pharmaceuticals has a normal ratio of the business financed by loans. This puts the company at some risk in periods of high inflation where borrowing costs usually go up. With a normal cash flow to debt ratio of 0.43, the company's ability to pay off the debt is normal. The company has a very low net profit margin of 4.82%, which is challenging.

We have calculated the inflation risk for Bafna Pharmaceuticals to be low [0.5 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.